Last reviewed · How we verify
COL-1620
COL-1620 is a selective inhibitor of collagen-producing fibroblasts that reduces excessive collagen deposition in fibrotic tissues.
COL-1620 is a selective inhibitor of collagen-producing fibroblasts that reduces excessive collagen deposition in fibrotic tissues. Used for Idiopathic pulmonary fibrosis (IPF).
At a glance
| Generic name | COL-1620 |
|---|---|
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Drug class | Antifibrotic agent |
| Modality | Small molecule |
| Therapeutic area | Fibrosis / Respiratory |
| Phase | Phase 3 |
Mechanism of action
COL-1620 targets pathological fibrosis by inhibiting fibroblast activation and collagen synthesis, thereby reducing tissue scarring and fibrotic remodeling. The drug is designed to modulate the fibrotic cascade in conditions characterized by excessive collagen accumulation. It represents a mechanism-based approach to treating progressive fibrotic diseases.
Approved indications
- Idiopathic pulmonary fibrosis (IPF)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COL-1620 CI brief — competitive landscape report
- COL-1620 updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI